CGTX — Cognition Therapeutics Share News
0.000.00%
Last trade - 00:00Cognition Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Cognition Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Cognition Therapeutics Says Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement In Cognitive Outcomes
Cognition Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Cognition Therapeutics Completes Enrollment In Phase II Shimmer Study Of CT1812 In Mild-To-Moderate Dementia
Cognition Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Cognition Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Cognition Therapeutics Says Pricing Of $11.5 Mln Public Offering Of Common Stock
Brief: Cognition Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Cognition Therapeutics Presents Preclinical Data on Alzheimer’S And Parkinson’S Diseases
Brief: Cognition Therapeutics Completes Enrollment In Phase 2 Shine Study Of CT1812 In Mild-To-Moderate Alzheimer’S Disease
Brief: Cognition Therapeutics Presents Complete EEG Findings From Sequel Study Of CT1812 In Mild-To-Moderate Alzheimer's Disease At CTAD
Cognition Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cognition Therapeutics Q2 Operating Expenses USD 11.817 Mln
Cognition Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Cognition Therapeutics Announces Dosing Of First Patient In Magnify Study Of Oral CT1812
Factbox: Companies in Alzheimer's race after US nod for Eisai/Biogen drug
Brief: Cognition Therapeutics And The Alzheimer's Clinical Trials Consortium Initiate First Clinical Site In The Phase 2 Start Study In Early Alzheimer’s Disease
U.S. STOCKS ON THE MOVE-Louisiana-Pacific, Jefferies Financial Group, Beazer Homes